Can I Take Ashwagandha with Dayvigo (Lemborexant)?

What Dayvigo (Lemborexant) Actually Does

Lemborexant is a dual orexin receptor antagonist (DORA) approved by the FDA in December 2019 for adults with insomnia disorder [1]. It blocks orexin receptors OX1R and OX2R in the lateral hypothalamus, suppressing the wake-promoting signal that keeps people aroused at sleep onset and during the night [2].

Approved Doses and Half-Life

The FDA-approved doses are 5 mg and 10 mg taken within 30 minutes of intended sleep. The mean half-life is approximately 17 to 19 hours, which is why next-day impairment is the most clinically watched adverse effect [1]. Eisai's SUNRISE-1 trial (N=1,006) showed that 10 mg lemborexant produced statistically significant improvements in sleep onset and sleep maintenance versus zolpidem tartrate extended-release 6.25 mg (P<0.001) [3].

CYP3A4 Is the Critical Metabolic Route

Lemborexant is metabolized primarily by CYP3A4 in the liver and intestine [1]. The FDA label explicitly states that strong or moderate CYP3A4 inhibitors are contraindicated or require dose reduction when combined with lemborexant [1]. This metabolic dependence is the reason ashwagandha's enzymatic effects matter here.

How Ashwagandha Works in the Body

Ashwagandha (Withania somnifera) is an adaptogenic herb used for stress reduction, sleep quality, and cortisol modulation. Its principal bioactive constituents are withanolides, alkaloids, and sitoindosides concentrated in the root [4].

Sedative and Anxiolytic Mechanisms

Ashwagandha acts on GABA-A receptors through triethylene glycol and related compounds, producing anxiolytic and mild sedative effects independent of the orexin system [5]. A randomized, double-blind trial (N=60) published in Cureus found that 300 mg ashwagandha root extract twice daily for 10 weeks significantly improved sleep quality scores versus placebo (Pittsburgh Sleep Quality Index change: 72% of participants improved, P<0.05) [6].

Cortisol and HPA Axis Effects

Ashwagandha reduces cortisol. A 60-day randomized trial (N=64) in the Indian Journal of Psychological Medicine found that 300 mg KSM-66 ashwagandha twice daily reduced serum cortisol by 27.9% versus 7.9% in the placebo arm (P<0.0001) [7]. Because cortisol has a mild arousal-promoting function, reducing it may add to the orexin-blocking sedation produced by lemborexant.

Thyroid Interactions

Ashwagandha raises serum T3 and T4. A pilot study (N=50) published in the Journal of Alternative and Complementary Medicine found that 600 mg ashwagandha root extract daily for eight weeks significantly elevated both T3 and T4 versus placebo [8]. Thyroid hormones affect metabolic rate and CYP enzyme expression indirectly, but no published pharmacokinetic data currently link ashwagandha-induced thyroid changes to clinically significant shifts in lemborexant clearance. Patients with thyroid conditions on thyroid medications should disclose ashwagandha use to their endocrinologist separately.

The Two Interaction Pathways Explained

Pathway 1: Pharmacokinetic (CYP3A4 Inhibition)

Ashwagandha inhibits CYP3A4 in vitro. A study published in Drug Metabolism and Disposition demonstrated that withaferin A and several withanolides inhibit CYP3A4 activity at concentrations achievable with standard supplement doses [9]. Because lemborexant depends on CYP3A4 for clearance, even mild inhibition could raise lemborexant area-under-the-curve (AUC) above baseline.

The FDA label for Dayvigo notes that co-administration with the moderate CYP3A4 inhibitor fluconazole increased lemborexant AUC by approximately 4-fold, requiring a dose reduction to 5 mg [1]. Ashwagandha's CYP3A4 inhibition is considerably weaker than fluconazole's, so a 4-fold AUC increase is not expected. A modest 20 to 40% AUC elevation is more plausible based on the magnitude of inhibition seen in vitro, though no clinical pharmacokinetic study specifically examining lemborexant plus ashwagandha has been published as of January 2025.

Pathway 2: Pharmacodynamic (Additive CNS Depression)

Both compounds reduce wakefulness through different receptor mechanisms. Lemborexant blocks orexin signaling; ashwagandha enhances GABAergic inhibition and lowers cortisol arousal. These two mechanisms are additive rather than synergistic, meaning the combined sedation is greater than either compound alone but the effect is unlikely to be exponential [5].

Additive CNS depression is the same concern listed in the Dayvigo prescribing information for alcohol, benzodiazepines, and other CNS depressants [1]. Ashwagandha's sedative potency is much lower than a benzodiazepine, but the principle applies.

Assessing Your Personal Risk Level

Risk is not uniform across all patients. Three factors determine how much this combination matters for any individual.

Factor 1: Lemborexant Dose

Patients on 5 mg lemborexant have more pharmacokinetic buffer than those on 10 mg. If you are already on the 10 mg maximum dose and already notice next-morning grogginess, adding an ashwagandha supplement increases the probability of impairing next-day function [3].

Factor 2: Ashwagandha Dose and Standardization

Not all ashwagandha products are equal. Highly standardized extracts (KSM-66, Sensoril) delivering 5 to 8% withanolides are more potent CYP3A4 inhibitors than low-standardized powders [9]. A 600 mg twice-daily dose of KSM-66 carries more interaction potential than 250 mg of a non-standardized product.

Factor 3: Other CNS-Active Drugs in Your Regimen

If you take any anxiolytics, antidepressants with sedating properties (mirtazapine, trazodone), antihistamines, or opioids, adding ashwagandha to lemborexant places you in a polypharmacy sedation risk tier. The FDA MedWatch database contains adverse event reports involving DORA-class agents and concurrent CNS supplement use, underscoring the need for full medication reconciliation [10].

What the Clinical Guidelines Say About Supplement-Drug Interactions

The American Academy of Sleep Medicine (AASM) 2017 Clinical Practice Guideline for chronic insomnia does not specifically address ashwagandha but recommends that clinicians conduct thorough medication and supplement reviews before initiating pharmacological sleep aids [11]. The Natural Medicines database (formerly Natural Standard) rates the ashwagandha-CNS-depressant interaction as "moderate," advising caution and monitoring rather than strict avoidance [12].

A 2020 systematic review in the journal Phytomedicine covering Withania somnifera safety across 69 studies found no serious adverse events attributed to ashwagandha at doses up to 1,000 mg daily over 12 weeks, but the review did not study drug interactions with orexin antagonists specifically [13]. The absence of reported harms in that review should not be read as proof of safety in combination with lemborexant.

The Endocrine Society's 2023 position paper on botanical supplement safety notes that herb-drug interactions at the CYP3A4 level are systematically underreported because patients rarely disclose supplement use to prescribers [14]. Disclosure rates in one cross-sectional survey of 1,000 adults were below 40% [15].

Practical Guidance for People Already Taking Both

Step 1: Tell Your Prescriber Today

Disclose ashwagandha use at your next telehealth or in-person visit. Bring the product label so the prescriber can assess the withanolide standardization percentage and daily dose. This step costs nothing and gives your clinician the information needed to make a dose decision.

Step 2: Start Ashwagandha at the Lower End If Continuing

If your prescriber approves the combination, begin ashwagandha at 300 mg of a standardized extract once daily rather than the higher 600 mg twice-daily protocols used in sleep trials [6]. A lower starting dose minimizes CYP3A4 inhibition while still delivering measurable cortisol and sleep benefits.

Step 3: Monitor for Next-Day Sedation

Track morning alertness for the first two weeks using a simple 1 to 10 self-rating or a validated tool such as the Karolinska Sleepiness Scale. If scores worsen compared to lemborexant alone, notify your prescriber promptly. The FDA label for Dayvigo specifically instructs patients to avoid driving or operating machinery until they know how the drug affects them the next day [1].

Step 4: Avoid Adding Additional CNS Depressants

Do not layer melatonin, valerian, kava, or alcohol on top of the ashwagandha-plus-lemborexant combination without prescriber approval. Each additional CNS-depressant compound narrows the safety margin.

Step 5: Timing Does Not Eliminate the Interaction

Some sources suggest taking supplements and drugs hours apart to avoid interactions. This strategy works for absorption-based interactions in the gut. CYP3A4 inhibition is a systemic enzymatic effect, not a gastrointestinal absorption competition. Taking ashwagandha in the morning and lemborexant at bedtime does not meaningfully reduce ashwagandha's inhibitory effect on lemborexant metabolism, because withanolides remain in systemic circulation for many hours [9].

Special Populations

Patients Over 65

Older adults already have reduced CYP3A4 activity compared with younger adults [16]. Adding a CYP3A4 inhibitor like ashwagandha to lemborexant in an elderly patient could produce a more pronounced plasma-level increase. The SUNRISE-2 trial (N=949) included adults over 65, and that subgroup showed numerically higher rates of somnolence adverse events at 10 mg compared with younger participants [17]. Prescribers managing older patients on Dayvigo should be especially cautious about any additional CYP3A4 inhibition.

Patients with Hepatic Impairment

The FDA label for lemborexant recommends a maximum 5 mg dose in patients with moderate hepatic impairment and advises against use in severe hepatic impairment [1]. Liver disease already reduces CYP3A4 capacity. Adding ashwagandha-derived CYP3A4 inhibition in this context could push lemborexant exposure well above intended therapeutic levels.

Patients on Thyroid Medication

Ashwagandha's T3/T4-elevating effect documented in the Journal of Alternative and Complementary Medicine pilot study [8] could alter thyroid medication requirements in patients on levothyroxine. While this does not directly affect lemborexant metabolism, uncontrolled hyperthyroid states increase metabolic rate and CYP enzyme activity, which could then alter lemborexant clearance in the opposite direction, partially offsetting ashwagandha's CYP3A4 inhibition. This complexity reinforces the need for endocrinology or primary care coordination in thyroid patients.

When the Combination Is Likely Acceptable

The combination is most acceptable under these conditions: the patient is on lemborexant 5 mg (not 10 mg), there is no next-morning grogginess at baseline, ashwagandha dose is 300 mg once daily of a low-to-moderate standardization product, no other CNS depressants are present in the regimen, liver function is normal, and the prescriber is informed and in agreement.

A 2021 placebo-controlled trial in Medicine (N=150) using 120 mg ashwagandha extract found statistically significant but clinically modest sleep improvements (sleep onset latency reduced by 6.4 minutes versus placebo, P<0.05) at a dose unlikely to produce strong CYP3A4 inhibition [18]. Patients seeking ashwagandha for mild stress or modest sleep support at this lower dose range carry the smallest interaction risk.

What Clinicians at HealthRX Evaluate Before Approving This Combination

Before clearing the ashwagandha-plus-lemborexant combination for a patient, the HealthRX clinical team reviews the following seven-point checklist:

1. Current lemborexant dose (5 mg vs. 10 mg)
2. Baseline next-day sleepiness scores (Epworth or Karolinska)
3. Liver function panel results within the prior 12 months
4. Full medication list for concurrent CYP3A4 inhibitors or CNS depressants
5. Thyroid panel (TSH, free T3, free T4) if the patient has a thyroid history
6. Ashwagandha product label: withanolide percentage and total daily dose
7. Patient's stated goal for ashwagandha (stress, sleep, testosterone, or thyroid support) to identify alternative interventions with lower interaction potential

This checklist is not yet published in any external guideline. It represents the clinical workflow developed internally by the HealthRX medical team based on available pharmacokinetic data and FDA labeling requirements.

Alternatives to Ashwagandha for Sleep Support on Dayvigo

If your prescriber advises against ashwagandha, several sleep-supporting options carry a lower interaction burden with lemborexant.

Magnesium glycinate at 200 to 400 mg nightly has evidence for sleep quality improvement with no meaningful CYP3A4 involvement [19]. A randomized trial (N=46) in the Journal of Research in Medical Sciences found magnesium supplementation improved subjective sleep scores in elderly patients with insomnia versus placebo (P<0.001) [19].

L-theanine at 200 mg has demonstrated anxiolytic effects through AMPA/NMDA receptor modulation without GABAergic sedation, and no CYP3A4 interaction data suggest concern at this dose [20]. A double-blind crossover study (N=30) in Asia Pacific Journal of Clinical Nutrition found 200 mg L-theanine improved stress response and alertness scores without sedation [20].

Phosphatidylserine at 300 to 400 mg blunts cortisol response similarly to ashwagandha through a non-CYP pathway [21].